This article is more than 5 years old. Information may no longer be current.
Zimmer Biomet receives FDA clearance for bone-preserving total shoulder arthroplasty solution
Click Here to Manage Email Alerts
Zimmer Biomet Holdings Inc. announced it has received FDA clearance for the Sidus stem-free shoulder system.
A total shoulder arthroplasty solution for patients with good bone stock who have either osteoarthritis, post-traumatic arthrosis, focal avascular necrosis of the humeral head or who had previous surgeries of the shoulder that do not compromise the fixation, the Sidus stem-free shoulder system is designed to anatomically restore a patient’s anatomy, preserve bone stock and allow for improved preoperative to postoperative patient outcomes, according to a company press release. The release noted that the Sidus system will be available in the United States beginning in the first quarter of 2018.
“The FDA clearance of the Sidus stem-free shoulder system comes at a time when Zimmer Biomet is accelerating the pace of innovation,” Bryan C. Hanson, president and CEO of Zimmer Biomet, said in the release. “We launched Sidus in Europe in 2012 and initiated a clinical study in the U.S. in 2015. During that time, the product has demonstrated strong clinical performance. The addition of the Sidus system to Zimmer Biomet’s U.S. portfolio reinforces the company’s leadership in the innovation of shoulder solutions.”
Reference: